Difference between revisions of "Team:ASIJ Tokyo"
| Line 9: | Line 9: | ||
} | } | ||
| − | #title p{ | + | #title p{ |
| − | + | font-size: 85px; | |
| − | + | color: #071f4e; | |
| − | + | position: absolute; | |
| − | + | top: 150px; | |
| − | + | left: 700px; | |
| − | + | font-weight: bold; | |
| − | + | font-family: "Avenir"; | |
| − | + | text-shadow: 4px 4px 7px #5a544b; | |
| − | + | letter-spacing: 15px; | |
| − | } | + | } |
| − | #red { | + | #red { |
| − | + | color: #c53d43; | |
| − | } | + | } |
| − | #subtitle h1{ | + | #subtitle h1{ |
| − | + | color: #071f4e; | |
| − | + | font-size: 20px; | |
| − | + | position: absolute; | |
| − | + | line-height: 2; | |
| − | + | top: 450px; | |
| − | + | left: 700px; | |
| − | } | + | } |
| − | #abstract { | + | #abstract { |
| − | + | position: relative; | |
| − | + | background-color: #bbbcde; | |
| − | + | padding: 10px; | |
| − | } | + | } |
| + | </style> | ||
| − | + | <head> | |
| − | + | <meta charset="utf-8"> | |
| − | + | <meta http-equiv="X-UA-Compatible" content="IE=edge"> | |
| − | + | <link href="https://fonts.googleapis.com/css?family=Quicksand:300,400,500,700" rel="stylesheet"> | |
| − | + | </head> | |
| − | + | ||
| − | + | <body bgcolor: #bce2e8> | |
| − | + | <div id="title"> | |
| − | + | <p>A1-AT<br>de<span id="red">LIVER</span>y </p> | |
| − | + | </div> | |
| − | + | <img src="https://static.igem.org/mediawiki/2018/e/ed/T--ASIJ_Tokyo--liverlogocut.png" id="liver"></img> | |
<div id="subtitle"> | <div id="subtitle"> | ||
<h1> Using Stem Cell and CRISPR Technology to Combat <br> Alpha-1 Antitrypsin Deficiency </h1> | <h1> Using Stem Cell and CRISPR Technology to Combat <br> Alpha-1 Antitrypsin Deficiency </h1> | ||
Revision as of 07:08, 31 August 2018
A1-AT
deLIVERy
